I am a molecular epidemiologist with a particular focus on cancer predisposition, and gene-environment interactions. I have published more than 380 publications on cancer genetics, causation of cancers of the colon, breast, lung, gynecological organs and the pancreato-hepato-biliary system. In addition, I am coordinating the cancer screening activities on a national level in Israel (from policy to implementationadherence, quality testing and outcomes measurement). I am and studying unique founder mutations leading to cancer through the Familial Cancer Consultation Service which I am directing and which cares for some 14000 risk families with thousands of cancer genes mutation carriers, including many patients with Lynch

Syndrome and the APC I1307K mutation. My work involves a deep epidemiological evaluation of more than 40,000 study participants combined with massive genetic testing using RT-PCR, Sanger sequencing, deep next-generation sequencing, microarray testing, multi-gene expression panels studies, Onco-chip multi-SNP panel, whole exome analysis and other laboratory methods. I have also studied colorectal cancer etiology (including gene-environment interactions) and the role of risk reducing medication in colorectal cancer and other tumors.

     I am involved in the identification of colorectal cancer patients and families with APC I1307K and other benign and pathogenic APC variants. Our population-based studies and clinical service have identified more than 800 carriers of APC 1307K, including 16 homozygotes and more than 100 Lynch Syndrome families with identified mutations in the MMR genes. My population based studies are involved in the CORECT and GECCO consortia of colorectal cancer research where 10,000 of our 14,000 participants in the Molecular Epidemiology of Colorectal Cancer (MECC) Study analyzed by various GWAS platforms, including the recent Illumina 500K OncoArray. Similarly, 4000 samples of our 16000 samples of the BCINIS (Breast Cancer in Northern Israel) Study participated in the NIH Game-On GWAS Initiative through the BCAC and CIMBA consortia and 1500 samples of our 3500 samples of the lung cancer study were studied with GWAS through the ILCCO consortium and we have also contributed ovarian cancer samples through OCAC consortia. We are now in process of testing 10,000 breast cancer samples with the NIH Confluence Project and a deep immunological investigation of a cohort of 1400 women with breast cancer detected before the age of 45, with the use the 770-gene panel of Nanostring (C360).